Tuccinardi Tiziano, Schenone Silvia, Bondavalli Francesco, Brullo Chiara, Bruno Olga, Mosti Luisa, Zizzari Alessandra Tania, Tintori Cristina, Manetti Fabrizio, Ciampi Osele, Trincavelli Maria Letizia, Martini Claudia, Martinelli Adriano, Botta Maurizio
Dipartimento di Scienze Farmaceutiche, Università degli Studi di Pisa, Via Bonanno 6, 56126 Pisa, Italy.
ChemMedChem. 2008 Jun;3(6):898-913. doi: 10.1002/cmdc.200700355.
Sixty-eight new substituted pyrazolo[3,4-b]pyridine derivatives were synthesized and tested for enriching a library of active A(1) adenosine receptor (AR) antagonists belonging to the same class. These compounds were also used as an external test set to check the reliability of a 3D QSAR model recently reported by us. To investigate the binding mode of pyrazolopyridine derivatives, a model of the bovine A(1)AR (bA(1)AR) was developed by a novel homology modeling approach and used to evaluate the main interactions of the ligands with the receptor through docking studies. Results suggest important interactions of the ligands mainly with L3.33(88), T3.36(91), Q3.37(92) and H6.52(251), in agreement with mutagenesis data. The racemic mixture of the most active compound was separated into the corresponding enantiomers which showed a bA(1)AR affinity in the nanomolar range, with the R enantiomer sevenfold more active than the S enantiomer, according to results derived from calculations on the receptor model. Analysis of the bovine/human A(1)AR affinity profile of ligands supported the hypothesis that such receptors should be characterized by a different size of their binding site, responsible for the different affinity of the antagonists.
合成了68种新的取代吡唑并[3,4 - b]吡啶衍生物,并对其进行测试,以充实属于同一类别的活性A(1)腺苷受体(AR)拮抗剂文库。这些化合物还用作外部测试集,以检验我们最近报道的一个3D QSAR模型的可靠性。为了研究吡唑并吡啶衍生物的结合模式,通过一种新颖的同源建模方法构建了牛A(1)AR(bA(1)AR)模型,并用于通过对接研究评估配体与受体的主要相互作用。结果表明,配体主要与L3.33(88)、T3.36(91)、Q3.37(92)和H6.52(251)存在重要相互作用,这与诱变数据一致。根据受体模型计算结果,将活性最高的化合物的外消旋混合物拆分为相应的对映体,这些对映体在纳摩尔范围内显示出对bA(1)AR的亲和力,其中R对映体的活性比S对映体高7倍。对配体的牛/人A(1)AR亲和力谱分析支持了这样一种假设,即此类受体的特征在于其结合位点大小不同,这导致了拮抗剂的亲和力差异。